社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
ZStarWyvernZ
IP属地:未知
+关注
帖子 · 11
帖子 · 11
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
ZStarWyvernZ
ZStarWyvernZ
·
2021-12-17
Cool
WHO and EMA could approve Novavax Covid vaccine next week
US drugmaker ‘confident’ as health bodies signal decisions are on the horizon Medical laboratory sci
WHO and EMA could approve Novavax Covid vaccine next week
看
2,093
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
ZStarWyvernZ
ZStarWyvernZ
·
2021-09-06
Cool
This Could Be Novavax's Ace in the Hole
Hint: It's not the company's COVID-19 vaccine. Key Points Novavax put its flu vaccine program on t
This Could Be Novavax's Ace in the Hole
看
1,091
回复
1
点赞
4
编组 21备份 2
分享
举报
ZStarWyvernZ
ZStarWyvernZ
·
2021-06-30
Cool
非常抱歉,此主贴已删除
看
1,644
回复
评论
点赞
5
编组 21备份 2
分享
举报
ZStarWyvernZ
ZStarWyvernZ
·
2021-06-23
Cool
非常抱歉,此主贴已删除
看
1,379
回复
1
点赞
3
编组 21备份 2
分享
举报
ZStarWyvernZ
ZStarWyvernZ
·
2021-06-22
Cool
非常抱歉,此主贴已删除
看
1,104
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
ZStarWyvernZ
ZStarWyvernZ
·
2021-06-21
Post
Global stocks slide after Wall Street frets about the Fed
Hong Kong (CNN Business)Global stocks and cryptocurrencies are pulling back on Monday as investors c
Global stocks slide after Wall Street frets about the Fed
看
1,350
回复
评论
点赞
1
编组 21备份 2
分享
举报
ZStarWyvernZ
ZStarWyvernZ
·
2021-06-21
Post
非常抱歉,此主贴已删除
看
1,330
回复
1
点赞
3
编组 21备份 2
分享
举报
ZStarWyvernZ
ZStarWyvernZ
·
2021-06-19
Comment
非常抱歉,此主贴已删除
看
1,604
回复
1
点赞
2
编组 21备份 2
分享
举报
ZStarWyvernZ
ZStarWyvernZ
·
2021-06-19
Post
3 Meme Stocks Wall Street Predicts Will Plunge More Than 20%
Meme stocks have been all the rage so far this year. That's understandable, with several of them del
3 Meme Stocks Wall Street Predicts Will Plunge More Than 20%
看
1,314
回复
1
点赞
2
编组 21备份 2
分享
举报
ZStarWyvernZ
ZStarWyvernZ
·
2021-06-18
Wew
Dow drops 400 points at the open, extending losses in its worst week since January
U.S. stocks fell on Friday with the Dow Jones Industrial Average on pace to post its worst week sinc
Dow drops 400 points at the open, extending losses in its worst week since January
看
1,190
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
加载更多
暂无粉丝
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3563667976523421","uuid":"3563667976523421","gmtCreate":1600574546003,"gmtModify":1600574546003,"name":"ZStarWyvernZ","pinyin":"zstarwyvernz","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":9,"headSize":572,"tweetSize":11,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.11","exceedPercentage":"93.50%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.22","exceedPercentage":"93.77%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":699030395,"gmtCreate":1639718854912,"gmtModify":1639718855043,"author":{"id":"3563667976523421","authorId":"3563667976523421","name":"ZStarWyvernZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563667976523421","authorIdStr":"3563667976523421"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699030395","repostId":"1116963836","repostType":4,"repost":{"id":"1116963836","kind":"news","pubTimestamp":1639696910,"share":"https://www.laohu8.com/m/news/1116963836?lang=&edition=full","pubTime":"2021-12-17 07:21","market":"us","language":"en","title":"WHO and EMA could approve Novavax Covid vaccine next week","url":"https://stock-news.laohu8.com/highlight/detail?id=1116963836","media":"Financial Times ","summary":"US drugmaker ‘confident’ as health bodies signal decisions are on the horizon\nMedical laboratory sci","content":"<div>\n<p>US drugmaker ‘confident’ as health bodies signal decisions are on the horizon\nMedical laboratory scientist Aniela Sobel tests serology samples from the Novavax phase 3 clinical trial in Seattle, ...</p>\n\n<a href=\"https://www.ft.com/content/a938950e-7f97-46d6-a22c-6933c5634842\">Web Link</a>\n\n</div>\n","source":"lsy1580170736413","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WHO and EMA could approve Novavax Covid vaccine next week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWHO and EMA could approve Novavax Covid vaccine next week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 07:21 GMT+8 <a href=https://www.ft.com/content/a938950e-7f97-46d6-a22c-6933c5634842><strong>Financial Times </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>US drugmaker ‘confident’ as health bodies signal decisions are on the horizon\nMedical laboratory scientist Aniela Sobel tests serology samples from the Novavax phase 3 clinical trial in Seattle, ...</p>\n\n<a href=\"https://www.ft.com/content/a938950e-7f97-46d6-a22c-6933c5634842\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.ft.com/content/a938950e-7f97-46d6-a22c-6933c5634842","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116963836","content_text":"US drugmaker ‘confident’ as health bodies signal decisions are on the horizon\nMedical laboratory scientist Aniela Sobel tests serology samples from the Novavax phase 3 clinical trial in Seattle, Washington © Karen Ducey/Getty\nThe approvals would provide the US drugmaker with a significant boost after months of delays and share price volatility amid manufacturing issues. The Covid-19 vaccine, also known as Nuvaxovid, would be the Maryland-based company’s first marketed product after more than three decades in business.\nA meeting of an EMA panel has been scheduled for Monday, the agency said, adding that it would communicate more details on that day provided there was a conclusion.\nSeparately, the WHO’s expert panel on vaccines met on Thursday to draft recommendations for use of the vaccine, with the WHO saying it would release its position “in the coming days”.\nWHO approval could come once the health body issued its own emergency use listing, or if the EMA gave it a conditional marketing authorisation, people familiar with the matter said.\nThe step would allow deliveries to begin via global vaccine access scheme Covax. Together with the Serum Institute of India, Novavax has a commitment to supply Covax with 1.1bn doses.\nTwo people familiar with both approval processes said there were still some “open questions” on manufacturing, but that the EMA should be able to issue a conditional approval. The open questions include so-called potency assays and drug substance characterisation — in essence, the ability of Novavax to ensure the product is the same everywhere and the same as that used in clinical studies.\nThe people said Novavax had acknowledged these points in meetings and was working to address them.\n“It’s nothing serious. It’s not different from situations we have seen with previous vaccines,” one of the people said, while also cautioning that an approval was not certain.\nNovavax said both approval processes would consider extensive data on manufacturing as well as clinical and pre-clinical data. The company was “confident that the vaccine meets the stringent regulatory quality, safety and efficacy specifications” needed for authorisation by the WHO and the EMA and it looked forward to their decisions.\nThe EMA declined to comment. The WHO said it would release its position “in the coming days”.\nOne of the people added that the EMA was “racing against time” as the vaccine, which would initially only be approved for a primary series or the first two shots for someone who has not been vaccinated, could play “an important role” this winter.\nThe Novavax shot has already been approved in the Philippines and Indonesia and the drugmaker has filed for approval in the UK. The company also expects to submit a complete application to the US Food and Drug Administration by year’s end.\nIn contrast to the novel mRNA vaccines made by Moderna and Pfizer, the Novavax shot uses a more traditional type of technology based on proteins and has been shown to be as much as 90.4 per cent effective in trials, including against previous variants of concern. The company is now testing its efficacy against the new Omicron variant.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2093,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":817838174,"gmtCreate":1630928951098,"gmtModify":1631890614097,"author":{"id":"3563667976523421","authorId":"3563667976523421","name":"ZStarWyvernZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563667976523421","authorIdStr":"3563667976523421"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/817838174","repostId":"1121589231","repostType":4,"repost":{"id":"1121589231","kind":"news","pubTimestamp":1630927585,"share":"https://www.laohu8.com/m/news/1121589231?lang=&edition=full","pubTime":"2021-09-06 19:26","market":"us","language":"en","title":"This Could Be Novavax's Ace in the Hole","url":"https://stock-news.laohu8.com/highlight/detail?id=1121589231","media":"Motley Fool","summary":"Hint: It's not the company's COVID-19 vaccine.\n\nKey Points\n\nNovavax put its flu vaccine program on t","content":"<blockquote>\n <b>Hint: It's not the company's COVID-19 vaccine.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Novavax put its flu vaccine program on the back burner after shifting to focus on COVID-19 in 2020.</li>\n <li>The company has already reported positive results from a late-stage study of its experimental NanoFlu flu vaccine.</li>\n <li>Novavax is moving forward with testing a COVID-19/flu combo that could potentially set the company apart from other vaccine makers.</li>\n</ul>\n<p><b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> </b>has its skeptics. Some point to the company's history of failure. Its respiratory syncytial virus (RSV) vaccine candidate ResVax experienced two clinical setbacks, and it haspushed back its anticipated timelinefor filing for Emergency Use Authorizations (EUAs) of its COVID-19 vaccine candidate NVX-CoV2373 three times.</p>\n<p>However, the future for this biotech stock could be brighter than many critics think. Novavax should file for EUA in the U.K. for NVX-CoV2373 within weeks, followed quickly by filings in the European Union and other countries.</p>\n<p>Its COVID-19 vaccine, while somewhat late to the party, could still be a commercial success for Novavax. But there's also another candidate in the company's pipeline that just might be its ace in the hole.</p>\n<p><b>A hot candidate on the back burner</b></p>\n<p>With all of the hubbub over NVX-CoV2373, it's easy to forget that it wasn't all that long ago that investors were excited about another experimental vaccine developed by Novavax. The company had high hopes for flu vaccine candidate NanoFlu after reporting encouraging results in early 2018 from a phase 1/2 study.</p>\n<p>Novavax advanced NanoFlu into phase 2 testing in older adults in September 2018. It reported more good news from that clinical trial in January 2019.</p>\n<p>That set the stage for NanoFlu's phase 3 study -- a head-to-head comparison with<b>Sanofi</b>'s approved flu vaccine FluZone Quadrivalent. The study began in October 2019. The following March, Novavax announced positive results, with NanoFlu clearly beating FluZone in the study's primary and secondary endpoints.</p>\n<p>The company seemed to be set to move quickly to file for approval of NanoFlu. However, its flu vaccine program was pushed to the back burner with Novavax moving forward with its COVID-19 vaccine development.</p>\n<p><b>A compelling combo</b></p>\n<p>It made sense that Novavax chose to focus on its COVID-19 program. The opportunity was too great to ignore, and Novavax's resources could only be spread out so far. And with the U.S. government throwing $1.6 billion the company's way to develop NVX-CoV2373, a shift in priorities was a no-brainer.</p>\n<p>However, Novavax certainly hasn't forgotten about NanoFlu. The company thinks that a combination COVID-19/flu vaccine featuring NVX-CoV2373 and NanoFlu could be a winner.</p>\n<p>Novavax has already announced promising preclinical data evaluating a NanoFlu/NVX-CoV2373 combination vaccine. It plans to initiate a phase 1 study in Australia later this year to evaluate the experimental combo.</p>\n<p>NanoFlu truly could be the key to Novavax setting itself apart from other COVID-19 vaccine makers.<b>Pfizer</b> and<b>BioNTech</b> are working on a flu vaccine candidate, but it hasn't advanced into clinical testing yet.<b>Moderna</b>only recently began early-stage clinical studies of its experimental flu vaccine.</p>\n<p>Meanwhile, Novavax has already demonstrated NanoFlu's safety and efficacy. It's also already moving ahead with clinical testing of a COVID-19/flu combo vaccine, something that rivals haven't done yet. Should annual boosters for COVID-19 be needed in the future, a combo COVID-19/flu vaccine could provide a compelling value proposition. Novavax appears to be the leader on this front.</p>\n<p><b>A good bet?</b></p>\n<p>I understand why some might be skeptical about Novavax considering the company's past track record. However, the company is in a better position than ever to succeed. Novavax has already reported positive results for NVX-CoV2373 from late-stage studies in the U.K. and the U.S. The primary hurdle now is to complete the regulatory filings for the vaccine.</p>\n<p>Assuming Novavax wins EUAs, it should be set to make a boatload of money. The company recently signed a deal with the European Union to supply 100 million doses initially and up to 100 million additional doses of NVX-CoV2373. Novavax could soon have ample financial resources to fund its COVID-19/flu combo vaccine program.</p>\n<p>It's not surprising at all to me that analysts are bullish about thevaccine stock. With the attractive prospects for NVX-CoV2373 and NanoFlu as its ace in the hole, Novavax appears to be a pretty good bet.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Could Be Novavax's Ace in the Hole</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Could Be Novavax's Ace in the Hole\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-06 19:26 GMT+8 <a href=https://www.fool.com/investing/2021/09/06/this-could-be-novavaxs-ace-in-the-hole/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hint: It's not the company's COVID-19 vaccine.\n\nKey Points\n\nNovavax put its flu vaccine program on the back burner after shifting to focus on COVID-19 in 2020.\nThe company has already reported ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/06/this-could-be-novavaxs-ace-in-the-hole/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/09/06/this-could-be-novavaxs-ace-in-the-hole/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121589231","content_text":"Hint: It's not the company's COVID-19 vaccine.\n\nKey Points\n\nNovavax put its flu vaccine program on the back burner after shifting to focus on COVID-19 in 2020.\nThe company has already reported positive results from a late-stage study of its experimental NanoFlu flu vaccine.\nNovavax is moving forward with testing a COVID-19/flu combo that could potentially set the company apart from other vaccine makers.\n\nNovavax has its skeptics. Some point to the company's history of failure. Its respiratory syncytial virus (RSV) vaccine candidate ResVax experienced two clinical setbacks, and it haspushed back its anticipated timelinefor filing for Emergency Use Authorizations (EUAs) of its COVID-19 vaccine candidate NVX-CoV2373 three times.\nHowever, the future for this biotech stock could be brighter than many critics think. Novavax should file for EUA in the U.K. for NVX-CoV2373 within weeks, followed quickly by filings in the European Union and other countries.\nIts COVID-19 vaccine, while somewhat late to the party, could still be a commercial success for Novavax. But there's also another candidate in the company's pipeline that just might be its ace in the hole.\nA hot candidate on the back burner\nWith all of the hubbub over NVX-CoV2373, it's easy to forget that it wasn't all that long ago that investors were excited about another experimental vaccine developed by Novavax. The company had high hopes for flu vaccine candidate NanoFlu after reporting encouraging results in early 2018 from a phase 1/2 study.\nNovavax advanced NanoFlu into phase 2 testing in older adults in September 2018. It reported more good news from that clinical trial in January 2019.\nThat set the stage for NanoFlu's phase 3 study -- a head-to-head comparison withSanofi's approved flu vaccine FluZone Quadrivalent. The study began in October 2019. The following March, Novavax announced positive results, with NanoFlu clearly beating FluZone in the study's primary and secondary endpoints.\nThe company seemed to be set to move quickly to file for approval of NanoFlu. However, its flu vaccine program was pushed to the back burner with Novavax moving forward with its COVID-19 vaccine development.\nA compelling combo\nIt made sense that Novavax chose to focus on its COVID-19 program. The opportunity was too great to ignore, and Novavax's resources could only be spread out so far. And with the U.S. government throwing $1.6 billion the company's way to develop NVX-CoV2373, a shift in priorities was a no-brainer.\nHowever, Novavax certainly hasn't forgotten about NanoFlu. The company thinks that a combination COVID-19/flu vaccine featuring NVX-CoV2373 and NanoFlu could be a winner.\nNovavax has already announced promising preclinical data evaluating a NanoFlu/NVX-CoV2373 combination vaccine. It plans to initiate a phase 1 study in Australia later this year to evaluate the experimental combo.\nNanoFlu truly could be the key to Novavax setting itself apart from other COVID-19 vaccine makers.Pfizer andBioNTech are working on a flu vaccine candidate, but it hasn't advanced into clinical testing yet.Modernaonly recently began early-stage clinical studies of its experimental flu vaccine.\nMeanwhile, Novavax has already demonstrated NanoFlu's safety and efficacy. It's also already moving ahead with clinical testing of a COVID-19/flu combo vaccine, something that rivals haven't done yet. Should annual boosters for COVID-19 be needed in the future, a combo COVID-19/flu vaccine could provide a compelling value proposition. Novavax appears to be the leader on this front.\nA good bet?\nI understand why some might be skeptical about Novavax considering the company's past track record. However, the company is in a better position than ever to succeed. Novavax has already reported positive results for NVX-CoV2373 from late-stage studies in the U.K. and the U.S. The primary hurdle now is to complete the regulatory filings for the vaccine.\nAssuming Novavax wins EUAs, it should be set to make a boatload of money. The company recently signed a deal with the European Union to supply 100 million doses initially and up to 100 million additional doses of NVX-CoV2373. Novavax could soon have ample financial resources to fund its COVID-19/flu combo vaccine program.\nIt's not surprising at all to me that analysts are bullish about thevaccine stock. With the attractive prospects for NVX-CoV2373 and NanoFlu as its ace in the hole, Novavax appears to be a pretty good bet.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1091,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153733101,"gmtCreate":1625048914403,"gmtModify":1631890614101,"author":{"id":"3563667976523421","authorId":"3563667976523421","name":"ZStarWyvernZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563667976523421","authorIdStr":"3563667976523421"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/153733101","repostId":"1150186389","repostType":4,"isVote":1,"tweetType":1,"viewCount":1644,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121125856,"gmtCreate":1624457166075,"gmtModify":1631890614103,"author":{"id":"3563667976523421","authorId":"3563667976523421","name":"ZStarWyvernZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563667976523421","authorIdStr":"3563667976523421"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/121125856","repostId":"1119538009","repostType":4,"isVote":1,"tweetType":1,"viewCount":1379,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129069547,"gmtCreate":1624344852389,"gmtModify":1631890614107,"author":{"id":"3563667976523421","authorId":"3563667976523421","name":"ZStarWyvernZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563667976523421","authorIdStr":"3563667976523421"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129069547","repostId":"1161710506","repostType":4,"isVote":1,"tweetType":1,"viewCount":1104,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167511571,"gmtCreate":1624276664893,"gmtModify":1631884647061,"author":{"id":"3563667976523421","authorId":"3563667976523421","name":"ZStarWyvernZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563667976523421","authorIdStr":"3563667976523421"},"themes":[],"htmlText":"Post","listText":"Post","text":"Post","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167511571","repostId":"1179311244","repostType":4,"repost":{"id":"1179311244","kind":"news","pubTimestamp":1624274237,"share":"https://www.laohu8.com/m/news/1179311244?lang=&edition=full","pubTime":"2021-06-21 19:17","market":"us","language":"en","title":"Global stocks slide after Wall Street frets about the Fed","url":"https://stock-news.laohu8.com/highlight/detail?id=1179311244","media":"CNN Business","summary":"Hong Kong (CNN Business)Global stocks and cryptocurrencies are pulling back on Monday as investors c","content":"<p>Hong Kong (CNN Business)Global stocks and cryptocurrencies are pulling back on Monday as investors continue to weigh signals from the Federal Reserve that it could raise interest rates sooner than expected.</p>\n<p>Markets were broadly lower, with Japan's Nikkei 225 (N225) dropping more than 3% — easily the worst major performer — after Wall Street closed out its worst week in months on Friday with a 1.6% fall on the Dow Jones Industrial Average (INDU).</p>\n<p>Hong Kong's Hang Seng (HSI) fell 1.1% and South Korea's Kospi (KOSPI) dropped 0.8%. China's Shanghai Composite (SHCOMP) was the regional outlier in Asia, up 0.1%.</p>\n<p>The fallout spilled over into Europe, where London's FTSE 100 (UKX) dropped 0.1%. France's CAC 40 (CAC40) fell 0.2%, while Germany's DAX (DAX) was up 0.2%.</p>\n<p>The declines followed volatility in the United States on Friday, where the Dow's weak close left it 3.5% lower on the week, its worst pullback since late January. The S&P 500 (SPX) lost 1.3% on Friday, while the Nasdaq Composite (COMP) shed 0.9%.</p>\n<p>US futures were muted early Monday, experiencing little change.</p>\n<p>Wall Street was already having a rough week, but stocks slid even further on Friday after St. Louis Federal Reserve President James Bullard told CNBC that he thinks the Fed should raise interest rates as soon as the end of next year. That was even more hawkish than the signal the Fed sent out on Wednesday that it may raise rates twice by late 2023.</p>\n<p>Wall Street is worried about inflation. But investors are also nervous about the Fed taking away the stimulus it is injecting into the market to counter the economic impact of the Covid-19 pandemic.</p>\n<p>The crypto market is also struggling Monday, though it wasn't immediately apparent why. Bitcoin is down more than 6% in the last 24 hours, trading just above $33,000 per coin, according to CoinDesk. Ethereum fell more than 7%, while dogecoin plunged more than 8%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Global stocks slide after Wall Street frets about the Fed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobal stocks slide after Wall Street frets about the Fed\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-21 19:17 GMT+8 <a href=https://edition.cnn.com/2021/06/21/investing/global-stocks-fed/index.html><strong>CNN Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hong Kong (CNN Business)Global stocks and cryptocurrencies are pulling back on Monday as investors continue to weigh signals from the Federal Reserve that it could raise interest rates sooner than ...</p>\n\n<a href=\"https://edition.cnn.com/2021/06/21/investing/global-stocks-fed/index.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite","SPY":"标普500ETF"},"source_url":"https://edition.cnn.com/2021/06/21/investing/global-stocks-fed/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1179311244","content_text":"Hong Kong (CNN Business)Global stocks and cryptocurrencies are pulling back on Monday as investors continue to weigh signals from the Federal Reserve that it could raise interest rates sooner than expected.\nMarkets were broadly lower, with Japan's Nikkei 225 (N225) dropping more than 3% — easily the worst major performer — after Wall Street closed out its worst week in months on Friday with a 1.6% fall on the Dow Jones Industrial Average (INDU).\nHong Kong's Hang Seng (HSI) fell 1.1% and South Korea's Kospi (KOSPI) dropped 0.8%. China's Shanghai Composite (SHCOMP) was the regional outlier in Asia, up 0.1%.\nThe fallout spilled over into Europe, where London's FTSE 100 (UKX) dropped 0.1%. France's CAC 40 (CAC40) fell 0.2%, while Germany's DAX (DAX) was up 0.2%.\nThe declines followed volatility in the United States on Friday, where the Dow's weak close left it 3.5% lower on the week, its worst pullback since late January. The S&P 500 (SPX) lost 1.3% on Friday, while the Nasdaq Composite (COMP) shed 0.9%.\nUS futures were muted early Monday, experiencing little change.\nWall Street was already having a rough week, but stocks slid even further on Friday after St. Louis Federal Reserve President James Bullard told CNBC that he thinks the Fed should raise interest rates as soon as the end of next year. That was even more hawkish than the signal the Fed sent out on Wednesday that it may raise rates twice by late 2023.\nWall Street is worried about inflation. But investors are also nervous about the Fed taking away the stimulus it is injecting into the market to counter the economic impact of the Covid-19 pandemic.\nThe crypto market is also struggling Monday, though it wasn't immediately apparent why. Bitcoin is down more than 6% in the last 24 hours, trading just above $33,000 per coin, according to CoinDesk. Ethereum fell more than 7%, while dogecoin plunged more than 8%.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"SPY":0.9}},"isVote":1,"tweetType":1,"viewCount":1350,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167513392,"gmtCreate":1624276538916,"gmtModify":1631884647066,"author":{"id":"3563667976523421","authorId":"3563667976523421","name":"ZStarWyvernZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563667976523421","authorIdStr":"3563667976523421"},"themes":[],"htmlText":"Post","listText":"Post","text":"Post","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/167513392","repostId":"1154249454","repostType":4,"isVote":1,"tweetType":1,"viewCount":1330,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":165375794,"gmtCreate":1624101549618,"gmtModify":1631890614107,"author":{"id":"3563667976523421","authorId":"3563667976523421","name":"ZStarWyvernZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563667976523421","authorIdStr":"3563667976523421"},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/165375794","repostId":"1156696708","repostType":4,"isVote":1,"tweetType":1,"viewCount":1604,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":165372670,"gmtCreate":1624101421390,"gmtModify":1631884647109,"author":{"id":"3563667976523421","authorId":"3563667976523421","name":"ZStarWyvernZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563667976523421","authorIdStr":"3563667976523421"},"themes":[],"htmlText":"Post","listText":"Post","text":"Post","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/165372670","repostId":"1166679093","repostType":4,"repost":{"id":"1166679093","kind":"news","pubTimestamp":1624065234,"share":"https://www.laohu8.com/m/news/1166679093?lang=&edition=full","pubTime":"2021-06-19 09:13","market":"us","language":"en","title":"3 Meme Stocks Wall Street Predicts Will Plunge More Than 20%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166679093","media":"fool","summary":"Meme stocks have been all the rage so far this year. That's understandable, with several of them del","content":"<p>Meme stocks have been all the rage so far this year. That's understandable, with several of them delivering triple-digit and even four-digit percentage gains.</p>\n<p>However, what goes up can come down. Analysts don't expect the online frenzy fueling the ginormous jumps for some of the most popular stocks will be sustainable. Here are three meme stocks that Wall Street thinks will plunge by more than 20% within the next 12 months.</p>\n<p>AMC Entertainment</p>\n<p><b>AMC Entertainment</b>(NYSE:AMC)ranks as the best-performing meme stock of all. Shares of the movie theater operator have skyrocketed close to 2,500% year to date.</p>\n<p>The consensus among analysts, though, is that the stock could lose 90% of its current value. Even the most optimistic analyst surveyed by Refinitiv has a price target for AMC that's more than 70% below the current share price.</p>\n<p>But isn't AMC's business picking up? Yep. The easing of restrictions has enabled the company to reopen 99% of its U.S. theaters. AMC could benefit as seating capacity limitations imposed by state and local governments are raised. Thereleases of multiple movies this summerand later this year that are likely to be hits should also help.</p>\n<p>However, Wall Street clearly believes that AMC's share price has gotten way ahead of its business prospects. The stock is trading at nearly eight times higher than it was before the COVID-19 pandemic.</p>\n<p>Clover Health Investments</p>\n<p>Only a few days ago, it looked like <b>Clover Health Investments</b>(NASDAQ:CLOV)might push AMC to the side as the hottest meme stock. Retail investors viewed Clover as a primeshort squeezecandidate.</p>\n<p>Since the beginning of June, shares of Clover Health have jumped more than 65%. Analysts, however, don't expect those gains to last. The average price target for the stock is 25% below the current share price.</p>\n<p>Clover Health's valuation does seem to have gotten out of hand. The healthcare stock currently trades at more than 170 times trailing-12-month sales. That's a nosebleed level, especially considering that the company is the subject of investigations by the U.S. Department of Justice and the Securities and Exchange Commission.</p>\n<p>Still, Clover Health could deliver improving financial results this year. The company hopes to significantly increase its membership by targeting the original Medicare program. This represents a major new market opportunity in addition to its current Medicare Advantage business.</p>\n<p>Sundial Growers</p>\n<p>At one point earlier this year, <b>Sundial Growers</b>(NASDAQ:SNDL)appeared to be a legitimate contender to become the biggest winner among meme stocks. The Canadian marijuana stock vaulted more than 520% higher year to date before giving up much of its gains. However, Sundial's share price has still more than doubled in 2021.</p>\n<p>Analysts anticipate that the pot stock could fall even further. The consensus price target for Sundial reflects a 23% discount to its current share price. One analyst even thinks the stock could sink 55%.</p>\n<p>There certainly are reasons to be pessimistic about Sundial's core cannabis business. The company's net cannabis revenue fell year over year in the first quarter of 2021. Although Sundial is taking steps that it hopes will turn things around, it remains to be seen if those efforts will succeed.</p>\n<p>Sundial's business deals could give investors reasons for optimism. After all, the company posted positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) in Q1 due to its investments.</p>\n<p>However, the cash that Sundial is using to make these investments has come at the cost of increased dilution of its stock. The company can't afford any additional dilution without having to resort to desperate measures to keep its listing on the <b>Nasdaq</b> stock exchange.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Meme Stocks Wall Street Predicts Will Plunge More Than 20%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Meme Stocks Wall Street Predicts Will Plunge More Than 20%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-19 09:13 GMT+8 <a href=https://www.fool.com/investing/2021/06/18/3-meme-stocks-wall-street-predicts-will-plunge-mor/><strong>fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Meme stocks have been all the rage so far this year. That's understandable, with several of them delivering triple-digit and even four-digit percentage gains.\nHowever, what goes up can come down. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/18/3-meme-stocks-wall-street-predicts-will-plunge-mor/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp","AMC":"AMC院线","SNDL":"SNDL Inc."},"source_url":"https://www.fool.com/investing/2021/06/18/3-meme-stocks-wall-street-predicts-will-plunge-mor/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166679093","content_text":"Meme stocks have been all the rage so far this year. That's understandable, with several of them delivering triple-digit and even four-digit percentage gains.\nHowever, what goes up can come down. Analysts don't expect the online frenzy fueling the ginormous jumps for some of the most popular stocks will be sustainable. Here are three meme stocks that Wall Street thinks will plunge by more than 20% within the next 12 months.\nAMC Entertainment\nAMC Entertainment(NYSE:AMC)ranks as the best-performing meme stock of all. Shares of the movie theater operator have skyrocketed close to 2,500% year to date.\nThe consensus among analysts, though, is that the stock could lose 90% of its current value. Even the most optimistic analyst surveyed by Refinitiv has a price target for AMC that's more than 70% below the current share price.\nBut isn't AMC's business picking up? Yep. The easing of restrictions has enabled the company to reopen 99% of its U.S. theaters. AMC could benefit as seating capacity limitations imposed by state and local governments are raised. Thereleases of multiple movies this summerand later this year that are likely to be hits should also help.\nHowever, Wall Street clearly believes that AMC's share price has gotten way ahead of its business prospects. The stock is trading at nearly eight times higher than it was before the COVID-19 pandemic.\nClover Health Investments\nOnly a few days ago, it looked like Clover Health Investments(NASDAQ:CLOV)might push AMC to the side as the hottest meme stock. Retail investors viewed Clover as a primeshort squeezecandidate.\nSince the beginning of June, shares of Clover Health have jumped more than 65%. Analysts, however, don't expect those gains to last. The average price target for the stock is 25% below the current share price.\nClover Health's valuation does seem to have gotten out of hand. The healthcare stock currently trades at more than 170 times trailing-12-month sales. That's a nosebleed level, especially considering that the company is the subject of investigations by the U.S. Department of Justice and the Securities and Exchange Commission.\nStill, Clover Health could deliver improving financial results this year. The company hopes to significantly increase its membership by targeting the original Medicare program. This represents a major new market opportunity in addition to its current Medicare Advantage business.\nSundial Growers\nAt one point earlier this year, Sundial Growers(NASDAQ:SNDL)appeared to be a legitimate contender to become the biggest winner among meme stocks. The Canadian marijuana stock vaulted more than 520% higher year to date before giving up much of its gains. However, Sundial's share price has still more than doubled in 2021.\nAnalysts anticipate that the pot stock could fall even further. The consensus price target for Sundial reflects a 23% discount to its current share price. One analyst even thinks the stock could sink 55%.\nThere certainly are reasons to be pessimistic about Sundial's core cannabis business. The company's net cannabis revenue fell year over year in the first quarter of 2021. Although Sundial is taking steps that it hopes will turn things around, it remains to be seen if those efforts will succeed.\nSundial's business deals could give investors reasons for optimism. After all, the company posted positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) in Q1 due to its investments.\nHowever, the cash that Sundial is using to make these investments has come at the cost of increased dilution of its stock. The company can't afford any additional dilution without having to resort to desperate measures to keep its listing on the Nasdaq stock exchange.","news_type":1,"symbols_score_info":{"AMC":0.9,"CLOV":0.9,"SNDL":0.9}},"isVote":1,"tweetType":1,"viewCount":1314,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166777674,"gmtCreate":1624026633798,"gmtModify":1631890614110,"author":{"id":"3563667976523421","authorId":"3563667976523421","name":"ZStarWyvernZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563667976523421","authorIdStr":"3563667976523421"},"themes":[],"htmlText":"Wew","listText":"Wew","text":"Wew","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166777674","repostId":"1118271544","repostType":4,"repost":{"id":"1118271544","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624023029,"share":"https://www.laohu8.com/m/news/1118271544?lang=&edition=full","pubTime":"2021-06-18 21:30","market":"us","language":"en","title":"Dow drops 400 points at the open, extending losses in its worst week since January","url":"https://stock-news.laohu8.com/highlight/detail?id=1118271544","media":"Tiger Newspress","summary":"U.S. stocks fell on Friday with the Dow Jones Industrial Average on pace to post its worst week sinc","content":"<p>U.S. stocks fell on Friday with the Dow Jones Industrial Average on pace to post its worst week since January, as bank shares led the market sell-off after the Federal Reserve's latest policy update.</p>\n<p>The blue-chip average dropped 400 points, bringing its week-to-date losses to 2.8% The S&P 500 fell 0.8%, pushing its loss this week to more than 1%. The tech-heavy Nasdaq Composite dipped 0.5%.</p>\n<p>Stocks extended their losses asSt. Louis Fed President Jim Bullard said on CNBCthat it was natural for the Fed to tilt a little \"hawkish\" this week and that the first rate increase from the central bank would likely come in 2022.</p>\n<p>Wall Street registered losses as the Federal Reserve on Wednesday afternoon added two rate hikes to its 2023 forecast and increased its inflation projection for the year.</p>\n<p>The decline in stocks came as the Fed's actions caused a drastic flattening of the so-called Treasury yield curve where the yields of shorter-duration Treasurys, like the 2-year note, rose, while longer duration yields, such as the benchmark 10-year, fell. The retreat in long-dated bonds reflects less optimism toward economic growth, while the jump in short-end yields shows the expectations of the Fed raising rates.</p>\n<p>This phenomenon is hurting bank stocks particularly as bank earnings could take a hit when the spread between short-term and long-term rates narrows. Goldman Sachs shares fell more than 1% Friday, while JPMorgan and Morgan Stanley also traded in the red.</p>\n<p>Fed Chairman Jerome Powell said on Wednesday that officials have discussed tapering bond buying and would at some point begin slowing the asset purchases.</p>\n<p>\"Investors may be interpreting the Fed's hawkish tilt Wednesday as a sign that an extended US post-pandemic economic expansion may be a bit harder to achieve in a potentially emerging environment of less accommodative monetary policy,\" said Goldman Sachs' Chris Hussey in a note.</p>\n<p>Most commodities prices rebounded a bit on Friday followingsharp declines this week as China attempts to cool rising prices and the U.S. dollar strengthens. Futures prices for copper, gold, and platinum rebounded Friday, but were still down big for the week.</p>\n<p>Chip stocks, which have had a good week, looked set to continue their run on Friday with shares of Nvidia higher by about 1%.</p>\n<p>Adobe shares gained about 3% after earnings and revenue topped estimates.</p>\n<p>Friday also coincides with the quarterly \"quadruple witching\" where options and futures on indexes and equities expire. Many expect trading to be more volatile in light of this event.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dow drops 400 points at the open, extending losses in its worst week since January</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDow drops 400 points at the open, extending losses in its worst week since January\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-18 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stocks fell on Friday with the Dow Jones Industrial Average on pace to post its worst week since January, as bank shares led the market sell-off after the Federal Reserve's latest policy update.</p>\n<p>The blue-chip average dropped 400 points, bringing its week-to-date losses to 2.8% The S&P 500 fell 0.8%, pushing its loss this week to more than 1%. The tech-heavy Nasdaq Composite dipped 0.5%.</p>\n<p>Stocks extended their losses asSt. Louis Fed President Jim Bullard said on CNBCthat it was natural for the Fed to tilt a little \"hawkish\" this week and that the first rate increase from the central bank would likely come in 2022.</p>\n<p>Wall Street registered losses as the Federal Reserve on Wednesday afternoon added two rate hikes to its 2023 forecast and increased its inflation projection for the year.</p>\n<p>The decline in stocks came as the Fed's actions caused a drastic flattening of the so-called Treasury yield curve where the yields of shorter-duration Treasurys, like the 2-year note, rose, while longer duration yields, such as the benchmark 10-year, fell. The retreat in long-dated bonds reflects less optimism toward economic growth, while the jump in short-end yields shows the expectations of the Fed raising rates.</p>\n<p>This phenomenon is hurting bank stocks particularly as bank earnings could take a hit when the spread between short-term and long-term rates narrows. Goldman Sachs shares fell more than 1% Friday, while JPMorgan and Morgan Stanley also traded in the red.</p>\n<p>Fed Chairman Jerome Powell said on Wednesday that officials have discussed tapering bond buying and would at some point begin slowing the asset purchases.</p>\n<p>\"Investors may be interpreting the Fed's hawkish tilt Wednesday as a sign that an extended US post-pandemic economic expansion may be a bit harder to achieve in a potentially emerging environment of less accommodative monetary policy,\" said Goldman Sachs' Chris Hussey in a note.</p>\n<p>Most commodities prices rebounded a bit on Friday followingsharp declines this week as China attempts to cool rising prices and the U.S. dollar strengthens. Futures prices for copper, gold, and platinum rebounded Friday, but were still down big for the week.</p>\n<p>Chip stocks, which have had a good week, looked set to continue their run on Friday with shares of Nvidia higher by about 1%.</p>\n<p>Adobe shares gained about 3% after earnings and revenue topped estimates.</p>\n<p>Friday also coincides with the quarterly \"quadruple witching\" where options and futures on indexes and equities expire. Many expect trading to be more volatile in light of this event.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118271544","content_text":"U.S. stocks fell on Friday with the Dow Jones Industrial Average on pace to post its worst week since January, as bank shares led the market sell-off after the Federal Reserve's latest policy update.\nThe blue-chip average dropped 400 points, bringing its week-to-date losses to 2.8% The S&P 500 fell 0.8%, pushing its loss this week to more than 1%. The tech-heavy Nasdaq Composite dipped 0.5%.\nStocks extended their losses asSt. Louis Fed President Jim Bullard said on CNBCthat it was natural for the Fed to tilt a little \"hawkish\" this week and that the first rate increase from the central bank would likely come in 2022.\nWall Street registered losses as the Federal Reserve on Wednesday afternoon added two rate hikes to its 2023 forecast and increased its inflation projection for the year.\nThe decline in stocks came as the Fed's actions caused a drastic flattening of the so-called Treasury yield curve where the yields of shorter-duration Treasurys, like the 2-year note, rose, while longer duration yields, such as the benchmark 10-year, fell. The retreat in long-dated bonds reflects less optimism toward economic growth, while the jump in short-end yields shows the expectations of the Fed raising rates.\nThis phenomenon is hurting bank stocks particularly as bank earnings could take a hit when the spread between short-term and long-term rates narrows. Goldman Sachs shares fell more than 1% Friday, while JPMorgan and Morgan Stanley also traded in the red.\nFed Chairman Jerome Powell said on Wednesday that officials have discussed tapering bond buying and would at some point begin slowing the asset purchases.\n\"Investors may be interpreting the Fed's hawkish tilt Wednesday as a sign that an extended US post-pandemic economic expansion may be a bit harder to achieve in a potentially emerging environment of less accommodative monetary policy,\" said Goldman Sachs' Chris Hussey in a note.\nMost commodities prices rebounded a bit on Friday followingsharp declines this week as China attempts to cool rising prices and the U.S. dollar strengthens. Futures prices for copper, gold, and platinum rebounded Friday, but were still down big for the week.\nChip stocks, which have had a good week, looked set to continue their run on Friday with shares of Nvidia higher by about 1%.\nAdobe shares gained about 3% after earnings and revenue topped estimates.\nFriday also coincides with the quarterly \"quadruple witching\" where options and futures on indexes and equities expire. Many expect trading to be more volatile in light of this event.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":1190,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"followers","isTTM":false}